Premium
LncRNA GClnc1 promotes proliferation and invasion of bladder cancer through activation of MYC
Author(s) -
Zhuang Chengle,
Ma Qian,
Zhuang Changshui,
Ye Jing,
Zhang Fangting,
Gui Yaoting
Publication year - 2019
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.201900078rr
Subject(s) - bladder cancer , cancer research , cancer , oncogene , metastasis , suppressor , long non coding rna , cell growth , biology , cell cycle , downregulation and upregulation , gene , genetics
ABSTRACT Various studies demonstrate that long noncoding RNAs (IncRNAs) act as oncogenes or tumor suppressors in cancer. However, the function of IncRNAs in bladder cancer still remains largely unknown. In this study, we identified an IncRNA, gastric cancer–associated IncRNA1 (GClnc1), which was in high abundance in bladder cancer tissues and its expression was related to poor survival rates in patients with bladder cancer. In vitro and in vivo assays showed that GClnc1 significantly promoted cell proliferation, metastasis, and invasiveness in bladder cancer. Mechanistically, we first found that GClnc1 bound to LIN28B and promoted the expression of myelocytomatosis proto‐oncogene (MYC) through the LIN28B/let‐7a/MYC pathway. In short, GClnc1 is clinically, functionally, and mechanistically oncogenic in bladder cancer. GClnc1 may be a potential target for treating patients with bladder cancer.—Zhuang, C., Ma, Q., Zhuang, C., Ye, J., Zhang, F., Gui, Y. LncRNA GClnc1 promotes proliferation and invasion of bladder cancer through activation of MYC. FASEB J. 33, 11045–11059 (2019). www.fasebj.org